The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront payment of $1.15 billion with milestone payments upwards of $450 million based on development and regulatory checkpoints. The deal is set to close in Q4 of 2025 and won’t drastically affect Sanofi’s financial guidance for 2025.

(Reuters) -French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total of $1.15 billion, expanding its respiratory vaccine portfolio.